trending Market Intelligence /marketintelligence/en/news-insights/trending/YJ4CzOwbtr5DTBdHhXxcNg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Amgen exits immuno-oncology collaboration with Advaxis

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Amgen exits immuno-oncology collaboration with Advaxis

Advaxis Inc. said Amgen Inc. withdrew from a collaboration to develop a customized cancer treatment.

Princeton, N.J.-based Advaxis will regain the worldwide rights to develop and commercialize ADXS-NEO, an immunotherapy designed to trigger the immune system's response against unique mutations contained and identified in the tumor.

Under the August 2016 agreement, Amgen paid $40 million up front and acquired $25 million Advaxis common shares.

In addition, Amgen reimbursed Advaxis for certain research and development costs related to the ADXS-NEO program. The reimbursements for fiscal year ended Oct. 31 reached about $5.8 million, along with $7.5 million in 2017, Advaxis noted.

The collaboration also allowed Advaxis to get future contingent payments based on development, regulatory and sales milestones.

The termination will be effective Feb. 8, 2019.

Advaxis is considering whether it will enter collaborations on the ADXS-NEO program which is currently enrolling patients.